Product logins

Find logins to all Clarivate products below.


Trauma Devices – Market Insights – Asia Pacific (Supplemental)

Growth in the Asia Pacific trauma device market will be supported by favorable demographics and rising adoption of innovative devices. However, several factors will dampen growth, such as the Chinese government’s volume-based procurement policy, which is placing downward pressure on ASPs in the country. In general, downward pricing pressures in various trauma device segments will partially offset the positive impact of procedure expansion and unit sales on revenues.

This Medtech 360 Report provides high-level market metrics for trauma devices in the Asia pacific region, including country-level data for major countries and aggregate data for the rest of the Asia pacific region from 2019 through 2033.

Table of contents


Related Medtech Insights Reports

Report
Gynecological Devices – Market Insights – Europe
The European gynecological device market will see marginal growth over the forecast period, fueled by the ongoing adoption of office-based treatments, the increasing preference for minimally…
Report
Sports Medicine Devices – Market Insights – Japan
Technological investments, adoption of premium-priced products, increased market awareness through educational programs, improved surgeon training, and high levels of sports participation will…
Report
Urological Devices – Market Insights – Europe
The European urological device market is set to grow through 2034, driven by product innovation, rising awareness, increasing kidney stone cases, and an aging population. Growth will be led by BPH…
Report
Diagnostic Imaging Systems – Market Insights – China
The diagnostic imaging system market in China will see moderate growth in the overall diagnostic imaging space through 2034, driven by favorable demographic trends and the accelerating adoption of…
Report
Interventional Oncology Devices – Market Insights – Europe
The European interventional oncology device market is projected to see modest growth through 2034, driven by rising cancer incidence and prevalence rates, updated clinical guidelines, and emerging…